Subscribe
KK Stock / Shutterstock.com
11 September 2024NewsAmericasLiz Hockley

Novo Nordisk files fresh lawsuits to intercept Wegovy generics

Danish multinational asks Delaware court to block semaglutide generics from Sun Pharma and Mylan | ANDAs infringe two claims of patent granted in July, Novo claims.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Novo Nordisk’s uphill battle in the counterfeit weight loss craze
12 July 2024   As the popularity of weight-loss drugs like Ozempic soars, the Danish company has to manage seasoned criminals and international investigations to get results, finds Marisa Woutersen.
Big Pharma
Ozempic counterfeits prompt Novo Nordisk to join forces with authorities
12 March 2024   Danish drugmaker testing suspect products and assisting with legal cases | High demand and global shortages have driven surge in weight-loss drug fakes.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
Novo Nordisk’s uphill battle in the counterfeit weight loss craze
12 July 2024   As the popularity of weight-loss drugs like Ozempic soars, the Danish company has to manage seasoned criminals and international investigations to get results, finds Marisa Woutersen.
Big Pharma
Ozempic counterfeits prompt Novo Nordisk to join forces with authorities
12 March 2024   Danish drugmaker testing suspect products and assisting with legal cases | High demand and global shortages have driven surge in weight-loss drug fakes.

More on this story

Big Pharma
Novo Nordisk’s uphill battle in the counterfeit weight loss craze
12 July 2024   As the popularity of weight-loss drugs like Ozempic soars, the Danish company has to manage seasoned criminals and international investigations to get results, finds Marisa Woutersen.
Big Pharma
Ozempic counterfeits prompt Novo Nordisk to join forces with authorities
12 March 2024   Danish drugmaker testing suspect products and assisting with legal cases | High demand and global shortages have driven surge in weight-loss drug fakes.

More features

Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages